Genesee Capital Advisors LLC Has $1.38 Million Stake in Cencora, Inc. (NYSE:COR)

Genesee Capital Advisors LLC trimmed its holdings in shares of Cencora, Inc. (NYSE:COR) by 0.8% during the fourth quarter, HoldingsChannel reports. The fund owned 6,140 shares of the company’s stock after selling 48 shares during the quarter. Genesee Capital Advisors LLC’s holdings in Cencora were worth $1,380,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Patriot Financial Group Insurance Agency LLC increased its position in Cencora by 5.6% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 4,206 shares of the company’s stock valued at $945,000 after purchasing an additional 223 shares during the period. Perigon Wealth Management LLC lifted its stake in shares of Cencora by 15.5% in the 4th quarter. Perigon Wealth Management LLC now owns 2,427 shares of the company’s stock valued at $585,000 after purchasing an additional 325 shares during the period. Pacer Advisors Inc. boosted its position in shares of Cencora by 6.7% during the 4th quarter. Pacer Advisors Inc. now owns 2,204,242 shares of the company’s stock valued at $495,249,000 after purchasing an additional 138,868 shares in the last quarter. KBC Group NV grew its stake in Cencora by 18.4% during the fourth quarter. KBC Group NV now owns 329,035 shares of the company’s stock worth $73,928,000 after purchasing an additional 51,112 shares during the period. Finally, Union Bancaire Privee UBP SA bought a new stake in Cencora in the fourth quarter worth approximately $2,892,000. Institutional investors own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

COR has been the subject of several research analyst reports. Wells Fargo & Company lowered their price objective on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a research note on Friday, December 13th. Barclays raised their target price on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Mizuho began coverage on Cencora in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price objective for the company. Evercore ISI lifted their price target on shares of Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Finally, UBS Group upped their price objective on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $277.00.

Cencora Price Performance

Shares of NYSE COR opened at $255.38 on Wednesday. The stock’s 50 day moving average price is $238.03 and its 200-day moving average price is $235.30. The company has a market capitalization of $49.36 billion, a PE ratio of 34.00, a PEG ratio of 1.54 and a beta of 0.49. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $256.81. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were given a dividend of $0.55 per share. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date of this dividend was Friday, November 15th. Cencora’s dividend payout ratio is currently 29.29%.

Insider Buying and Selling at Cencora

In related news, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now owns 20,329 shares in the company, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total value of $5,208,619.44. Following the transaction, the chairman now directly owns 306,752 shares of the company’s stock, valued at $74,283,064.32. The trade was a 6.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 73,187 shares of company stock worth $17,790,912 over the last ninety days. 15.80% of the stock is currently owned by company insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.